GlassScriptPhysician profile
Daniel Bernard Mendlovic
NPI 1427121599
$1,195.63
in general payments reported to CMS, 2019-2025
14 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $16.87 · 2021: $17.06 · 2022: $121 · 2023: $419 · 2024: $72.37 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712 · Education: $79.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.53 |
| Education | $79.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $209.22 | 2022-2023 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $209.03 | 2019-2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $202.32 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $138.16 | 2025 | Twiist |
| Amgen INC. | $95.83 | 2019 | |
| Mannkind Corporation | $77.25 | 2025 | |
| Lilly USA, LLC | $63.31 | 2023-2025 | Mounjaro, Zepbound |
| Amryt Pharma Holdings LTD | $55.35 | 2022 | |
| Corcept Therapeutics | $41.71 | 2024-2025 | Korlym |
| Abbott Laboratories | $23.76 | 2023 | Freestyle Libre 3 |
| Beta Bionics, INC. | $23.66 | 2023 | Ilet Bionic Pancreas |
| Medtronic, INC. | $21.60 | 2023 | Minimed 780g |
| Antares Pharma, INC. | $17.97 | 2024 | Xyosted |
| Ascensia Diabetes Care US INC. | $16.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mendlovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.